HEMANG MAISURIA, Director, Global Safety Lead, Servier Pharmaceuticals

“Dr. Hemang Maisuria is a seasoned professional with over 25 years of experience within the pharmaceutical arena. In addition to his clinical background, he has also completed his JD in Health Law and Intellectual Property. He is currently serving as a Director and Global Safety Lead for Servier Pharmaceuticals; responsible for their lead IDH1 inhibitor product Tibsovo. He oversees the benefit / risk portfolio of the product as well as the strategic management of the product lifecycle. He previously managed this product at Agios Pharmaceuticals, and was transitioned to Servier following the acquisition of the asset by Servier last year. Prior to joining Agios, he was the Director of Drug Safety / Pharmacovigilance and Risk Management at Amneal Pharmaceuticals. In this capacity he was responsible for global pharmacovigilance activities including Labeling, REMS, Medical Information, and Analytics for Amneal.

Dr. Maisuria has extensive CRO experience as well, having led the establishment and growth of the first US based full service pharmacovigilance provider; inclusive of technology, processes and personnel, called Sentrx. In his role as VP of Commercial Development, he has engaged with industry leaders and provided his expertise in establishing full PV capabilities for over 50+ large and small pharma companies.

Dr. Maisuria has also served as an Adjunct Professor at LIU and Rutgers University in their pharmacy programs, and as a mentor for his students during their academic career and beyond.”